DIALINE LOW CALCIUM PERITONEAL DIALYSIS SOLUTION WITH 4.25 % DEXSTROSE

Valsts: Izraēla

Valoda: angļu

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

CALCIUM CHLORIDE; GLUCOSE HYDROUS; LACTIC ACID AS SODIUM; MAGNESIUM CHLORIDE; SODIUM CHLORIDE

Pieejams no:

TEVA MEDICAL LTD

ATĶ kods:

B05XA31

Zāļu forma:

SOLUTION FOR PERITONEAL DIALYSIS

Kompozīcija:

GLUCOSE HYDROUS 4.25 G / 100 ML; MAGNESIUM CHLORIDE 5.08 MG / 100 ML; SODIUM CHLORIDE 538 MG / 100 ML; LACTIC ACID AS SODIUM 448 MG / 100 ML; CALCIUM CHLORIDE 18.3 MG / 100 ML

Ievadīšanas:

PERITONEAL DIALYSIS

Receptes veids:

Required

Ražojis:

TEVA MEDICAL LTD, ISRAEL

Ārstniecības grupa:

ELECTROLYTES IN COMBINATION WITH OTHER DRUGS

Ārstniecības joma:

ELECTROLYTES IN COMBINATION WITH OTHER DRUGS

Ārstēšanas norādes:

For use in chronic renal failure patient being maintained in peritoneal dialysis.

Autorizācija datums:

2012-05-31

Produkta apraksts

DIALINE
® LOW CALCIUM PERITONEAL DIALYSIS SOLUTIONS
(2.5% MEQ/L CALCIUM)
DIALINE
® LOW CALCIUM PERITONEAL DIALYSIS SOLUTION WITH 1.5% DEXTROSE.
DIALINE
® LOW CALCIUM PERITONEAL DIALYSIS SOLUTION WITH 2.5% DEXTROSE.
DIALINE
® LOW CALCIUM PERITONEAL DIALYSIS SOLUTION WITH 4.25% DEXTROSE.
FOR PERITONEAL DIALYSIS
FOR INTRAPERITONEAL ADMINISTRATION ONLY
DESCRIPTION
DIALINE Low Calcium peritoneal dialysis solutions are sterile,
nonpyrogenic solutions in plastic containers for intraperitoneal
administration only. They contain no bacteriostatic
or antimicrobial agents or added buffers.
Composition, calculated osmolarity, pH and ionic concentrations are
shown in Table 1.
Potassium is omitted from peritoneal dialysis solutions because
dialysis may be performed to correct hyperkalemia. In situations in
which there is a normal serum potassium
level or hypokalemia, the addition of potassium chloride (up to a
concentration of 4 mEq/L) may be indicated to prevent severe
hypokalemia.
ADDITION OF POTASSIUM CHLORIDE SHOULD BE MADE AFTER CAREFUL EVALUATION
OF SERUM AND TOTAL BODY POTASSIUM AND ONLY UNDER THE DIRECTION OF A
PHYSICIAN. Frequent
monitoring of serum electrolytes is indicated.
In some patients calcium carbonate is used as a phosphate binder.
Because serum calcium levels have been observed to be elevated in
these patients (Slatopolsky et al.
1986), the calcium concentration of DIALINE Low Calcium peritoneal
dialysis solutions has been appropriately reduced to 2.5 mEq/L. Serum
calcium levels should be
monitored and if low, the amount of oral calcium carbonate phosphate
binder may be increased or peritoneal dialysis solutions containing
higher calcium concentrations may
be used. If serum calcium levels rise, adjustments to the dosage of
the calcium carbonate phosphate binder and/or vitamin D analogs should
be considered by the physician.
Because average plasma magnesium levels in some chronic CAPD patients
have been observed to be elevated (Nolph et al. 1981), the magnesium
concentration of this
formulation has been re